The influence of adjuvant radiotherapy on patterns of failure and survivals in uterine carcinosarcoma |
Park, Hae-Jin
(Department of Radiation Oncology, Seoul National University College of Medicine)
Kim, Hak-Jae (Department of Radiation Oncology, Seoul National University College of Medicine) Wu, Hong-Gyun (Department of Radiation Oncology, Seoul National University College of Medicine) Kim, Hans (Department of Radiation Oncology, Seoul National University College of Medicine) Ha, Sung-Whan (Department of Radiation Oncology, Seoul National University College of Medicine) Kang, Soon-Beom (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) Song, Yong-Sang (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) Park, Noh-Hyun (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) Kim, Jae-Won (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) |
1 | Garcia-Martinez E, Egea Prefasi L, Garcia-Donas J, Escolar- Perez PP, Pastor F, Gonzalez-Martin A. Current management of uterine sarcomas. Clin Transl Oncol 2011;13:307-14. DOI ScienceOn |
2 | George E, Lillemoe TJ, Twiggs LB, Perrone T. Malignant mixed mullerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival. Int J Gynecol Pathol 1995;14:39-44. DOI ScienceOn |
3 | Vaidya AP, Horowitz NS, Oliva E, Halpern EF, Duska LR. Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma. Gynecol Oncol 2006;103:684-7. DOI ScienceOn |
4 | Sampath S, Schultheiss TE, Ryu JK, Wong JY. The role of adjuvant radiation in uterine sarcomas. Int J Radiat Oncol Biol Phys 2010;76:728-34. DOI ScienceOn |
5 | Reed NS, Mangioni C, Malmstrom H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008;44:808-18. DOI ScienceOn |
6 | Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81. DOI ScienceOn |
7 | Makker V, Abu-Rustum NR, Alektiar KM, et al. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. Gynecol Oncol 2008; 111:249-54. DOI ScienceOn |
8 | Sartori E, Bazzurini L, Gadducci A, et al. Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecol Oncol 1997;67:70-5. DOI ScienceOn |
9 | Wolfson AH, Brady MF, Rocereto T, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 2007;107:177-85. DOI ScienceOn |
10 | Clayton Smith D, Kenneth Macdonald O, Gaffney DK. The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma. Radiother Oncol 2008;88:227- 32. DOI ScienceOn |
11 | Wong L, See HT, Khoo-Tan HS, Low JS, Ng WT, Low JJ. Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed mullerian tumors of the uterus. Int J Gynecol Cancer 2006;16:1364-9. DOI ScienceOn |
12 | McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002;12:687-90. DOI ScienceOn |
13 | Manolitsas TP, Wain GV, Williams KE, Freidlander M, Hacker NF. Multimodality therapy for patients with clinical Stage I and II malignant mixed Mullerian tumors of the uterus. Cancer 2001;91:1437-43. DOI ScienceOn |
14 | Menczer J, Levy T, Piura B, et al. A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol 2005;97:166-70. DOI ScienceOn |
15 | Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 2000;88:2782-6. DOI ScienceOn |
16 | Arrastia CD, Fruchter RG, Clark M, et al. Uterine carcinosarcomas: incidence and trends in management and survival. Gynecol Oncol 1997;65:158-63. DOI ScienceOn |
17 | Pothuri B, Ramondetta L, Eifel P, et al. Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers. Gynecol Oncol 2006;103:948-51. DOI ScienceOn |
18 | Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ. Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys 2004;58:786-96. DOI ScienceOn |
19 | Silverberg SG, Major FJ, Blessing JA, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: a Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990;9:1-19. DOI |
20 | McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 2002;55:321-5. DOI ScienceOn |
21 | Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 2009;105:107- 8. DOI ScienceOn |
![]() |